Relationship Between IDH1 Mutation and Clinic Pathologic Features in Human Supratentorial WHO Grade Ⅱ Gliomas

TANG Jun-jia, XIE Fei, WANG Xiang, ZHANG Dou-dou, LIU Shuang, LIU Yan-hui, MAO Qing

Abstract

To investigate the relationship between isocitrate dehydrogenase 1 (IDH1) mutation and clinicopathological features in human supratentorial WHO gradeⅡ gliomas. Methods Ninety five supratentorial WHO gradeⅡ glioma patients were treated in our department from January 2009 to January 2011. The clinical data and tumor samples of each patient were collected. IDH1 mutation in the tumor was measured by sequencing the IDH1 gene of tumor specimen. The relationship between IDH1 mutation and the clinicopathological features was analyzed. Results There were 69 cases (72.6%) with IDH1 mutations were found, all of which were R132H type mutations. The mutation rates of diffuse astrocytoma, oligodendroglioma and oligoastrocytoma were 73.6%, 68.8% and 73.1% respectively. The mean ages of IDH1 mutant group and wild type group were significantly different[(39.6±7.4) yr. vs. (46.9±11.6) yr., P<0.05]. The mutant rates of patients aged ≥ 50 years and <50 years were 43.8% and 78.5% respectively (P<0.05), while those of male patients and female patients were 68.6% and 77.3% respectively (P>0.05). The mutant rates of patients whose tumor ≥ 5 cm and <5 cm were 60.0% and 90.0% respectively (P<0.05), while those of monolobe involvement group and deepen structures involvement group were 93.3% and 32.0% respectively (P<0.05). Conclusion The mutation of IDH1 in supratentorial WHO gradeⅡglioma is common, and is associated with patients' age, tumor size and tumor location.

 

 Keywords: Isocitrate dehydrogenase 1 gene, WHO gradeⅡglioma, Clinic pathologic features

 

Full Text:

PDF


References


Louis DN, Ohgaki H. Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropat hoi, 2007; 114 ( 2 ) : 97-109.

Bourne TD. Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol, 2010;6(12):695-701.

Horbinski C, Kelly L, Nikiforov YE, et al. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn, 2010; 12(4) ;487-492.

Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008; 321 (5897);1807-1812.

Yan H, Parsons W, Jin G, et al. IDH1 and IDH2 mutation in gliomas. N Engl J Med.2009;360(8):765-773.

Watanabe T, Nobusawa S, Kleihues P. et al. IDH 1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol ,2009; 174(4); 1149-1153.

Nikiforova MN. Hamilton RL. Molecular diagnostics of gliomas. Arch Pathol Lab Med,2011; 135(5);558-568.

Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH 1 dominantly inhibit IDH 1 catalytic activity and induce HIF-la. Science,2009;324(5924):261-265.

Blass J. Meyer J, Mueller W. et al. Analysis of the IDH 1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116(6);597-602.

Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol,2010; 120(6);719-729.

Zlatescu MC, TehraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res, 2001; 61 ( 18); 6713- 6715.

Chang EF. Clark A, Jensen RL, et al. Multiinstitutional validation of the University of California at San Francisco Low- Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg.2009; 111(2) :203-2l0.

Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg,2008; 109(5);817-824.

Pignatti F. van den Bent M. Curran D. et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol.2002;20(8):2076-2084.


Refbacks

  • There are currently no refbacks.